Membrane proteins are notoriously difficult targets for antibody discovery.
How is our antibody discovery platform unique and tailored to membrane proteins?
MPS Antibody Discovery
"Integral's technology platform for antibody discovery was uniquely suited to our needs. The degree to which Integral's team engaged with us on scientific direction and design was unexpected but extremely beneficial."
What makes our approach so successful for complex proteins?
High Titer Responses
Using targeted high-throughput mutagenesis strategies, we engineer membrane proteins as needed to improve their surface expression and stability and to reduce toxicity. Highly expressed antigens result in higher titer immune responses.Learn about our antigen engineering strategies
Our proprietary immunization protocols combine DNA immunization and antigen presentation on Lipoparticles with proprietary adjuvants. This antibody elicitation strategy ensures a robust immune response focused against the native extracellular regions of the protein.
Use of Divergent Species
We can immunize evolutionarily divergent species to obtain high-titer responses, even for highly conserved, poorly immunogenic targets. This strategy provides broad epitope diversity and favors generation of MAbs with dual specificity for human and rodent orthologs, thereby avoiding the need for surrogate MAbs for animal studies.
Rare MAb Isolation
Microfluidic B-cell Cloning
Our proprietary microfluidic B-cell cloning platform enables millions of B cells to be screened directly from immunized animals. This process allows us to isolate rare functional antibodies with native VH+VL pairing.
Phage Display using Lipoparticles
Our phage display protocols are specifically designed to isolate challenging antibodies against native membrane proteins embedded in a lipid bilayer. Using these strategies, we can isolate diverse panels of antibodies against membrane proteins with a success rate exceeding 95%.
What antibody discovery services do we offer?
Full MPS Antibody Discovery Services
Full antibody discovery services are available for customer-specified targets. We tailor our solutions to the challenges of your specific target to ensure success. We begin with antigen optimization, perform immunizations using proprietary protocols, and deliver validated IgG leads. We also offer functional screening, antibody humanization, affinity maturation, and epitope and paratope mapping services.
Antigen Optimization Services
We provide antigen optimization services for challenging protein targets, customizing our antigen engineering approaches to your protein target. Solutions may include a combination of rational and high-throughput mutagenesis strategies.
Antibody Engineering Services
We offer antibody engineering services to increase affinity, specificity, and stability. Our antibody engineering approaches are adapted to your goals and may include combinations of random, designed, and high-throughput mutagenesis strategies.
Frequently Asked Questions
The final deliverable of an MPS Antibody Discovery project is usually a panel of highly specific, diverse, and functional MAbs that meet the customer’s specifications. Using our MPS Antibody Discovery platform, we have a very high success rate (>95%) in delivering such MAb panels. In addition to the final deliverable, customers receive 4 progress reports during their MPS project:
- 1. Target Expression Report – Summarizes target expression after engineering and the proposed immunization strategy
- 2. Serum Reactivity Report – Summarizes the immune response of each animal to the target protein
- 3. Clone Screen Report – Summarizes MAb selection results and the diversity of discovered MAbs
- 4. Clone Reactivity Report – Summarizes target reactivity and the full sequence of each validated MAb. This report is provided simultaneously with 100 μg of purified, ready-to-use IgG of each validated MAb for customer testing